Search | Clinical Trials Finder

Conditions: Crohn's Disease
Interventions: MEDI2070, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 26
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 22 more

Conditions: Crohn's Disease
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 45
States / cities: Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more

Conditions: Ulcerative Colitis (UC)
Interventions: risankizumab IV, placebo for risankizumab, risankizumab SC; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 82
States / cities: Coronado, California • Irvine, California • La Jolla, California + 63 more

Conditions: Low Back Pain
Interventions: Fasinumab, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 35 Years and older
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 58
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more

Conditions: Asthma
Interventions: TEV-48574, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 55
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 47 more

Conditions: Healthy
Interventions: PRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose; Drug
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more

Conditions: Crohn's Disease
Interventions: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 111
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin; Drug · Other · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Rheumatoid Arthritis
Interventions: Golimumab, Methotrexate, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 20
States / cities: Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more

Conditions: Crohn's Disease
Interventions: placebo for risankizumab IV, risankizumab SC, risankizumab IV; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 114
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 89 more

Conditions: Atopic Dermatitis
Interventions: FB825 or Placebo in subcutaneous route, FB825 in intravenous route; Drug
Lead sponsor: Oneness Biotech Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions: Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 1,718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 79
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more

Conditions: Myasthenia Gravis, Generalized
Interventions: Claseprubart, Placebo, Claseprubart, Placebo; Drug · Combination Product
Lead sponsor: Dianthus Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Pasadena, California • Boca Raton, Florida • Fayetteville, North Carolina + 1 more

Conditions: Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Interventions: Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab; Drug · Other · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Duarte, California • Tampa, Florida • Buffalo, New York + 1 more

Conditions: Leukemia, Myeloid, Acute
Interventions: glasdegib, daunorubicin + cytarabine, azacitidine, Placebo, cytarabine, HSCT; Drug · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 30
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 14 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Familial Partial Lipodystrophy, Metabolic Abnormalities
Interventions: REGN4461, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Boca Raton, Florida • Bethesda, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Warm Autoimmune Hemolytic Anemia
Interventions: ALXN1830, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Riverside, California

Conditions: InFertility
Interventions: Pulsatile gonadotropin-releasing hormone (GnRH), Clomiphene Citrate, Placebo Pulsatile GnRH, Placebo Clomiphene Citrate; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Overweight, Obesity
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Chula Vista, California • Long Beach, California • San Diego, California + 7 more

Conditions: Human Immuno-deficiency Virus (HIV) Disease
Interventions: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: HIV-1-infection
Interventions: SAR441236, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Search by objective public record fields.

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Pharmacokinetics and Safety of SAR441236